IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series
Objective There is currently no evidence of the possible benefit of plasma cell–targeting therapies (PCTT) in immunoglobulin A (IgA) monoclonal gammopathy (MG) associated with IgA vasculitis (IgAV). We report the outcome of different PCTT regimens in a cohort of MG-IgAV. Methods We used a French network to retrospectively describe the outcome of MG-IgAV patients treated with PCTT. Results Five patients were included (mean age 65 years). All patients had severe baseline presentation including extensive necrotic purpura (n = 5), gastrointestinal involvement (n = 2), peripheral neuropathies (n = 2), and glomerulonephritis (n = 1). Two patients had IgA indolent multiple myeloma and three had IgA “MG of undetermined significance.” Monotypic IgA deposition in the skin vessels wall was highlighted using an immunofluorescence assay. Cases of vasculitis in three patients (n = 3) were refractory to multiple line therapies, including cyclophosphamide (n = 3) or rituximab. Finally, PCTT including bortezomib plus cyclophosphamide and dexamethasone, bortezomib plus melphalan and prednisone, or bortezomib plus lenalidomide and dexamethasone were proposed, allowing complete remission in 4/5 patients without major adverse drug events. Conclusion This study suggests that the MG-IgAV phenotype might be distinctive of usual IgAV (severe and refractory to conventional immunosuppressive regimens) and supports the benefit of PCTT. This study sheds new light on the overall biology of IgAV, strengthening the pathogenic role of the monoclonal IgA component in IgAV..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 41(2022), 10 vom: 17. Juni, Seite 3119-3123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hankard, Antoine [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Gammopathy |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022 |
|---|
| doi: |
10.1007/s10067-022-06181-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048142549 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048142549 | ||
| 003 | DE-627 | ||
| 005 | 20230519191316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220920s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-022-06181-4 |2 doi | |
| 035 | |a (DE-627)SPR048142549 | ||
| 035 | |a (SPR)s10067-022-06181-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hankard, Antoine |e verfasserin |0 (orcid)0000-0003-2305-7117 |4 aut | |
| 245 | 1 | 0 | |a IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022 | ||
| 520 | |a Objective There is currently no evidence of the possible benefit of plasma cell–targeting therapies (PCTT) in immunoglobulin A (IgA) monoclonal gammopathy (MG) associated with IgA vasculitis (IgAV). We report the outcome of different PCTT regimens in a cohort of MG-IgAV. Methods We used a French network to retrospectively describe the outcome of MG-IgAV patients treated with PCTT. Results Five patients were included (mean age 65 years). All patients had severe baseline presentation including extensive necrotic purpura (n = 5), gastrointestinal involvement (n = 2), peripheral neuropathies (n = 2), and glomerulonephritis (n = 1). Two patients had IgA indolent multiple myeloma and three had IgA “MG of undetermined significance.” Monotypic IgA deposition in the skin vessels wall was highlighted using an immunofluorescence assay. Cases of vasculitis in three patients (n = 3) were refractory to multiple line therapies, including cyclophosphamide (n = 3) or rituximab. Finally, PCTT including bortezomib plus cyclophosphamide and dexamethasone, bortezomib plus melphalan and prednisone, or bortezomib plus lenalidomide and dexamethasone were proposed, allowing complete remission in 4/5 patients without major adverse drug events. Conclusion This study suggests that the MG-IgAV phenotype might be distinctive of usual IgAV (severe and refractory to conventional immunosuppressive regimens) and supports the benefit of PCTT. This study sheds new light on the overall biology of IgAV, strengthening the pathogenic role of the monoclonal IgA component in IgAV. | ||
| 650 | 4 | |a Gammopathy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Henoch-Schönlein purpura |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IgA vasculitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunoglobulin A |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monoclonal plasma cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multiple myeloma |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ingen-Housz-Oro, Saskia |4 aut | |
| 700 | 1 | |a El Karoui, Khalil |4 aut | |
| 700 | 1 | |a Paule, Romain |4 aut | |
| 700 | 1 | |a Lioger, Bertrand |4 aut | |
| 700 | 1 | |a Brihaye, Benoit |4 aut | |
| 700 | 1 | |a Battistella, Maxime |4 aut | |
| 700 | 1 | |a Jobard, Stéphanie |4 aut | |
| 700 | 1 | |a Magnant, Julie |4 aut | |
| 700 | 1 | |a Diot, Elisabeth |4 aut | |
| 700 | 1 | |a Bigot, Adrien |4 aut | |
| 700 | 1 | |a Ferreira-Maldent, Nicole |4 aut | |
| 700 | 1 | |a Deriaz, Sophie |4 aut | |
| 700 | 1 | |a Cook, Ann-Rose |4 aut | |
| 700 | 1 | |a Henique, Hélène |4 aut | |
| 700 | 1 | |a Maillot, Francois |4 aut | |
| 700 | 1 | |a Aouba, Achille |4 aut | |
| 700 | 1 | |a Audemard-Verger, Alexandra |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d London : Springer, 1982 |g 41(2022), 10 vom: 17. Juni, Seite 3119-3123 |w (DE-627)SPR008480389 |w (DE-600)1480901-1 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:10 |g day:17 |g month:06 |g pages:3119-3123 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10067-022-06181-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 10 |b 17 |c 06 |h 3119-3123 | ||